Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Abuse-Deterrent Formulations Could Become Prerequisite To Approval

Executive Summary

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee recommends against approval of Zogenix’s Zohydro ER as it seeks safer formulations and stricter REMS for all extended-release/long-acting opioids.

Advertisement

Related Content

Zogenix Zohydro Launch Will Test FDA’s Balanced Approach On Opioid Pain Reviews
FDA Decision Delay On Zohydro ER: No News May Be Good News
FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics
FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake
Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant
OxyContin Abuse-Deterrent Formulation Has Addicts Switching To Heroin
One-Page MedGuide For Long-acting Opioids Sets Stage For Retooling MedGuide Format
Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH
Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves
FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel